ALPHARETTA, Ga., Aug. 3 /PRNewswire/ -- Alliant Pharmaceuticals, Inc. a pediatric specialty pharmaceutical company, has acquired RONDEC(R), a medication for cold and allergy symptoms, from Biovail Corp. , a specialty pharmaceutical company based in Ontario, Canada.
RONDEC syrup and oral drops, (Brompheniramine maleate, Pseudoephedrine hydrochloride, Dextromethorphan hydrobromide, Carbinoxamine maleate) are decongestant and antihistamine combinations used to treat the symptoms associated with seasonal rhinitis (hay fever) and other types of inflammation in the nose.
Dr. Dennis Spangler, Chief Medical Officer of the Atlanta Allergy & Asthma Clinic states, "The Rondec line of liquid oral antihistamine, decongestant and antitussive combinations are very familiar to the Pediatric community. They are recognized for their effectiveness, and ease of use. It should be favorably received when the pediatricians are made aware that these products are again available as a treatment for the respiratory symptoms of their patients."
"We are excited to have RONDEC among our family of products," stated Mark Pugh, President of Alliant Pharmaceuticals. "RONDEC has been a gold standard in treating pediatric patients with cold and allergy symptoms for many years. The addition fits solidly with our strategic vision of being a leading provider of pediatric medications."
Pugh added that the move to sell RONDEC by Biovail was the result of a strategic change within Biovail. The Canadian company specializes in oral controlled-release drug deliveries, and focuses on medications within pain management, cardiovascular and central nervous system.
The terms of the deal were not disclosed. Alliant will begin marketing RONDEC actively this fall.
About Alliant Pharmaceuticals, Inc.
Alliant Pharmaceuticals, Inc. is a Specialty Pharmaceutical company formed to develop and market a portfolio of innovative pharmaceutical products to pediatricians and pediatric specialty physicians. Alliant Pharmaceuticals focuses on identifying opportunities to acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfill unmet medical needs. Additional information about Alliant Pharmaceuticals in available online at: http://www.alliantphrama.com.
For more information, contact
Sharon Kraun, InSight Communications
678.468.0064 / skraun@bellsouth.net
Alliant Pharmaceuticals, Inc.CONTACT: Sharon Kraun of InSight Communications, +1-678-468-0064, orskraun@bellsouth.net
Web site: http://www.alliantpharma.com/
